val-cit-pab-mmaf

Val-Cit-PAB-MMAF is an agent-linker conjugate utilized for antibody-drug conjugates (ADCs), consisting of the peptide linker Val-Cit-PAB and the potent tubulin polymerization inhibitor known as MMAF [1].

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

DBCO-PEG4-Val-Cit-PAB-MMAF is a chemical compound consisting of a cleavable 4 unit polyethylene glycol antibody-drug conjugate (ADC) linker (DBCO-PEG4-Val-Cit-PAB) and a potent inhibitor of tubulin polymerization (MMAF). This compound is an essential component in the synthesis of ADCs.

Mal-PEG8-Val-Cit-PAB-MMAF, a drug-linker conjugate utilized for antibody-drug conjugates (ADCs), includes a cleavable linker system and the potent tubulin inhibitor monomethyl auristatin F (MMAF), designed for targeted cancer therapy.

Val-Cit-PAB-MMAF sodium is an agent-linker conjugate used in antibody-drug conjugates (ADCs), comprising the peptide linker Val-Cit-PAB and the cytotoxic agent monomethyl auristatin F (MMAF), which inhibits tubulin polymerization [1].